Axogen Share Price (NASDAQ: AXGN)

$16.06

▲

-0.15

(-0.93%)

Live

Last updated on August 28, 2025 at 1:29 am IST

$₹

Check the interactive Axogen Stock chart to analyse performance

Axogen stock performance

as on August 28, 2025 at 1:29 am IST

Today's Low:$15.92
Today's High:$16.20
$16.06
0.87%
Downside
Day's Volatility :1.73%
Upside
0.86%
52 Weeks Low:$9.22
52 Weeks High:$21.00
$16.06
42.62%
Downside
52 Weeks Volatility :56.12%
Upside
23.52%

Axogen Stock Returns

Period	Axogen, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	47.95%	3.7%	0.0%
6 Months	-16.68%	-6.9%	0.0%
1 Year	27.58%	-11.9%	0.0%
3 Years	82.81%	7.7%	-6.9%

Axogen, Inc. Key Stats

Check Axogen key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$16.21
Open	$16.2
Today's High	$16.27
Today's Low	$15.92
Market Capitalization	$748.2M
Today's Volume	$1.5M
52 Week High	$21.0
52 Week Low	$9.215
Revenue TTM	$203.3M
EBITDA	$8.6M
Earnings Per Share (EPS)	$-0.1
Profit Margin	-2.29%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-4.48%

Stock Returns calculator for Axogen Stock including INR - Dollar returns

The Axogen stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Axogen investment value today

Current value as on today

₹1,31,030

Returns

₹31,030

(+31.03%)

Returns from Axogen Stock

₹26,357 (+26.36%)

Dollar Returns*

₹4,673 (+4.67%)

Indian investors sentiment towards Axogen Stock

467%

Period: Jul 27, 2025 to Aug 26, 2025. Change in 30 Days versus previous period

Search interest for Axogen Stock from India on INDmoney has increased by 467% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Axogen, Inc.

Name
Holdings %
Name
Holdings %
First Light Asset Management, LLC
9.84%
BlackRock Inc
7.72%
Vanguard Group Inc
5.93%
Morgan Stanley - Brokerage Accounts
5.65%
ArrowMark Colorado Holdings, LLC (ArrowMark Partners)
3.53%
Soleus Capital Management, L.P.
3.17%

Analyst Recommendation on Axogen Stock

Rating

Trend

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Axogen(by analysts ranked 0 to 5 stars)

Axogen Share Price Target

What analysts predicted

Upside of 53.89%

Target:

$24.71

Current:

$16.06

Axogen share price target is $24.71, a slight Upside of 53.89% compared to current price of $16.06 as per analysts' prediction.

Axogen Stock Insights

Price Movement
In the last 1 month, AXGN stock has moved up by 21.3%
Increasing Revenue
Revenue is up for the last 2 quarters, 48.56M → 56.66M (in $), with an average increase of 14.3% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -3.83M → 579.0K (in $), with an average increase of 762.2% per quarter
AXGN vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 33.3% return, outperforming this stock by 5.7%
AXGN vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 162.6% return, outperforming this stock by 86.3%
Price to Sales
ForAXGN every $1 of sales, investors are willing to pay $3.6, whereas for Boston Scientific Corp., the investors are paying $8.5 for every $1 of sales.

Axogen, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$106.7M	↑ 27.13%
Net Income	$-29.1M	↑ 30.03%
Net Profit Margin	-27.29%	↓ 0.61%

	FY20	Y/Y Change
Revenue	$112.3M	↑ 5.24%
Net Income	$-23.8M	↓ 18.32%
Net Profit Margin	-21.18%	↑ 6.11%

	FY21	Y/Y Change
Revenue	$127.4M	↑ 13.41%
Net Income	$-27.0M	↑ 13.45%
Net Profit Margin	-21.19%	↓ 0.01%

	FY22	Y/Y Change
Revenue	$138.6M	↑ 8.81%
Net Income	$-28.9M	↑ 7.27%
Net Profit Margin	-20.89%	↑ 0.3%

	FY23	Y/Y Change
Revenue	$159.0M	↑ 14.74%
Net Income	$-21.7M	↓ 24.98%
Net Profit Margin	-13.66%	↑ 7.23%

	FY24	Y/Y Change
Revenue	$187.3M	↑ 17.81%
Net Income	$-10.0M	↓ 54.12%
Net Profit Margin	-5.32%	↑ 8.34%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$41.4M	↓ 3.6%
Net Income	$-6.6M	↑ 70.43%
Net Profit Margin	-16.04%	↓ 6.97%

	Q2 FY24	Q/Q Change
Revenue	$47.9M	↑ 15.79%
Net Income	$-1.9M	↓ 71.05%
Net Profit Margin	-4.01%	↑ 12.03%

	Q3 FY24	Q/Q Change
Revenue	$48.6M	↑ 1.53%
Net Income	$-1.9M	↓ 3.28%
Net Profit Margin	-3.82%	↑ 0.19%

	Q4 FY24	Q/Q Change
Revenue	$49.4M	↑ 1.56%
Net Income	$450.0K	↓ 124.22%
Net Profit Margin	0.91%	↑ 4.73%

	Q1 FY25	Q/Q Change
Revenue	$48.6M	↓ 1.71%
Net Income	$-3.8M	↓ 952.0%
Net Profit Margin	-7.9%	↓ 8.81%

	Q2 FY25	Q/Q Change
Revenue	$56.7M	↑ 16.68%
Net Income	$579.0K	↓ 115.1%
Net Profit Margin	1.02%	↑ 8.92%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$89.4M	↑ 25.84%

	FY20	Y/Y Change
Profit	$90.7M	↑ 1.52%

	FY21	Y/Y Change
Profit	$104.4M	↑ 15.11%

	FY22	Y/Y Change
Profit	$114.4M	↑ 9.59%

	FY23	Y/Y Change
Profit	$127.9M	↑ 11.74%

	FY24	Y/Y Change
Profit	$142.0M	↑ 11.03%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$32.6M	↓ 3.39%

	Q2 FY24	Q/Q Change
Profit	$35.3M	↑ 8.35%

	Q3 FY24	Q/Q Change
Profit	$36.4M	↑ 3.09%

	Q4 FY24	Q/Q Change
Profit	$37.6M	↑ 3.12%

	Q1 FY25	Q/Q Change
Profit	$34.9M	↓ 7.03%

	Q2 FY25	Q/Q Change
Profit	$42.0M	↑ 20.28%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-19.9M	↑ 11.25%
Investing Cash Flow	$27.3M	↓ 127.77%
Financing Cash Flow	$4.0M	↓ 96.33%

	FY20	Y/Y Change
Operating Cash Flow	$-9.6M	↓ 51.56%
Investing Cash Flow	$-17.0M	↓ 162.2%
Financing Cash Flow	$40.5M	↑ 904.07%

	FY21	Y/Y Change
Operating Cash Flow	$-13.4M	↑ 39.26%
Investing Cash Flow	$-23.6M	↑ 39.42%
Financing Cash Flow	$20.5M	↓ 49.47%

	FY22	Y/Y Change
Operating Cash Flow	$-16.1M	↑ 19.85%
Investing Cash Flow	$-3.2M	↓ 86.47%
Financing Cash Flow	$1.8M	↓ 91.23%

	FY23	Y/Y Change
Operating Cash Flow	$-5.7M	↓ 64.42%
Investing Cash Flow	$19.3M	↓ 701.66%
Financing Cash Flow	$2.0M	↑ 8.92%

	FY24	Y/Y Change
Operating Cash Flow	$4.5M	↓ 179.34%
Investing Cash Flow	$-10.3M	↓ 153.48%
Financing Cash Flow	$2.3M	↑ 17.2%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-12.3M	↑ 5713.27%
Investing Cash Flow	$-3.3M	↑ 1073.65%
Financing Cash Flow	$204.0K	↓ 51.2%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$4.2M	↓ 133.96%
Investing Cash Flow	$-1.2M	↓ 62.07%
Financing Cash Flow	$544.0K	↑ 166.67%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$3.9M	↓ 6.34%
Investing Cash Flow	$-5.0M	↑ 305.52%
Financing Cash Flow	$572.0K	↑ 5.15%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$8.7M	↑ 123.92%
Investing Cash Flow	$-813.0K	↓ 83.74%
Financing Cash Flow	$970.0K	↑ 69.58%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-13.2M	↓ 250.88%
Investing Cash Flow	$1.3M	↓ 264.7%
Financing Cash Flow	$2.4M	↑ 145.57%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$7.7M	↓ 158.65%
Investing Cash Flow	$-6.9M	↓ 618.82%
Financing Cash Flow	$1.2M	↓ 51.43%

Axogen Technicals Summary

Sell

Neutral

Buy

Axogen is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Axogen, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Axogen, Inc.	24.83%	-16.68%	27.58%	82.81%	38.59%
Medtronic Plc	0.22%	1.76%	3.8%	3.67%	-14.54%
Edwards Lifesciences Corp.	3.54%	12.94%	16.72%	-10.06%	-3.63%
Boston Scientific Corp.	0.54%	4.78%	33.3%	163.46%	159.35%
Stryker Corporation	-1.53%	0.72%	10.05%	90.79%	99.06%
Abbott Laboratories	4.16%	-3.2%	16.37%	29.23%	18.79%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Axogen, Inc.	NA	NA	0.0	0.26	-0.04	0.01	NA	2.45
Medtronic Plc	25.61	25.61	2.16	5.46	0.1	0.04	0.03	37.46
Edwards Lifesciences Corp.	34.0	34.0	4.83	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.57	62.57	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.64	51.64	2.24	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.55	16.55	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Axogen, Inc.	Buy	$748.2M	38.59%	NA	-2.29%
Medtronic Plc	Buy	$118.8B	-14.54%	25.61	13.63%
Edwards Lifesciences Corp.	Buy	$47.7B	-3.63%	34.0	72.96%
Boston Scientific Corp.	Buy	$155.7B	159.35%	62.57	13.55%
Stryker Corporation	Buy	$149.4B	99.06%	51.64	12.25%
Abbott Laboratories	Buy	$229.5B	18.79%	16.55	32.43%

About Axogen, Inc.

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.

Organization	Axogen
Employees	451
CEO	Mr. Michael D. Dale
Industry	Health Technology

Key Management of Axogen, Inc.

Name	Title
Mr. Michael D. Dale	President, CEO & Director
Mr. Marc A. Began	Executive VP, General Counsel & Chief Compliance Officer
Mr. Jens Schroeder Kemp	Chief Marketing Officer
Mr. Erick DeVinney	Chief Innovation Officer
Ms. Lindsey Hartley CPA	Chief Financial Officer
Mr. Craig A. Swandal	Vice President of Operations
Mr. Harold D. Tamayo M.B.A.	Vice President of Finance & Investor Relations
Ms. Doris Quackenbush	Vice President of Sales
Dr. Ivica Ducic M.D., Ph.D.	Chief Medical Officer

Important FAQs about investing in AXGN Stock from India :

What is Axogen share price today?

Axogen share price today is $16.06 as on August 28, 2025 at 1:29 am IST. Axogen share today touched a day high of $16.20 and a low of $15.92.

What is the 52 week high and 52 week low for Axogen share?

Axogen share touched a 52 week high of $21.00 and a 52 week low of $9.22. Axogen stock price today i.e. August 28, 2025 at 1:29 am IST is trending at $16.06, lower by 23.52% versus the 52 week high.

How to invest in Axogen Stock (AXGN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Axogen on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Axogen Shares that will get you 0.0934 shares as per Axogen share price of $16.06 per share as on August 28, 2025 at 1:29 am IST.

What is the minimum amount required to buy Axogen Stock (AXGN) from India?

Indian investors can start investing in Axogen (AXGN) shares with as little as ₹87.86 or $1 (as of August 27, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹878.60 in Axogen stock (as per the Rupee-Dollar exchange rate as on August 27, 2025). Based on Axogen share’s latest price of $16.06 as on August 28, 2025 at 1:29 am IST, you will get 0.6227 shares of Axogen. Learn more about fractional shares .

What are the returns that Axogen has given to Indian investors in the last 5 years?

Axogen stock has given 38.59% share price returns and 18.89% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?